Phenomenex Case Study Documents Cost-Saving API Residual Analysis
Complete the form below to unlock access to ALL audio articles.
Phenomenex Inc., has announced the publication of a case study, written by scientists at Pfizer, that demonstrates the results of a new method for residual API (active pharmaceutical ingredient) analysis.
This new solution replaces 16 older methods for individual key ingredients, and has delivered cost savings of £320,000 (more than $516,000) per year.
The method requires just one UHPLC instrument, using Phenomenex Kinetex® 1.7-micron core-shell columns, to resolve all 16 ingredients in just six minutes.
In addition to instrument and time savings, the method uses less solvent, reduces waste disposal costs and frees up lab analysts. The method can be reviewed and /or downloaded at: http://www.phenomenex.com/info/form/casestudy.
“High-volume laboratories, such as those in pharmaceutical QC, have an acute need to reduce operating costs and free up resources,” explains Jeremy Bierman, brand manager for HPLC products.
Bierman continued, “The Kinetex core-shell technology allows the development of faster and more efficient analytical methods to deliver significant cost and time savings.”
The Kinetex 1.7-micron column is the first and only sub-2-micron core-shell UHPLC column on the market and typically delivers efficiency gains of 15 to 20 percent over traditional fully porous sub-2-micron columns.
